Rexahn presents preliminary data from ongoing Phase 2a trial of RX-3117
Rexahn Pharmaceuticals announced earlier that preliminary safety and efficacy data from the ongoing Phase 2a clinical trial of RX-3117 in combination with Abraxane in patients newly diagnosed with metastatic pancreatic cancer were being presented in a poster presentation at the fifth NCI Pancreatic Cancer Symposium held October 2-3, 2018 at the National Institutes of Health. "These preliminary data are encouraging, showing that the combined administration of RX-3117 and Abraxane in newly diagnosed metastatic pancreatic cancer patients appears to be safe and well tolerated and showing evidence of clinical activity. As of September 19, 2018, there was one complete response and three partial responses from the first 14 evaluable patients. In addition, there were eight patients with stable disease who had tumor reductions of up to 16% and who are still being actively dosed. We are encouraged by this preliminary data reflecting a disease control rate of 86% and an overall response rate of 29%. We look forward to completing the study enrollment and plan to report the final data in 2019," said Dr. Ely Benaim, M.D., chief medical officer of Rexahn. "The safety profile of RX-3117 continues to be encouraging as it can be administered at its recommended Phase 2 dose together with the maximal labeled dose of Abraxane without producing an increase in severe adverse events. This differs from current standard of care where the doses of both gemcitabine and Abraxane, when given in combination, may have to be reduced to avoid grade 3 and 4 dose limiting toxicities," added CEO Peter Suzdak.